ClinicalTrials.gg
Not yet recruitingNCT07614360DREAMM-16Updated Jun 24, 2026

Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 2 interventional study of Belantamab mafodotin and Dexamethasone in Multiple Myeloma, sponsored by GlaxoSmithKline. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Planned enrollment
8th of 49
150 · median 50
Started
2026
with 6 others
Phase 2
12 of 49
7 open now
Primary completion
2029-02
later than 26 of 34 live
Registered
46th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 8th largest by planned enrollment, is one of 7 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 26 of the 34 other live ones, and was the 46th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

The aim of this study is to assess safety, efficacy and pharmacokinetic (PK) parameters with alternative dosing schedules of belantamab mafodotin in combination with bortezomib and dexamethasone compared to the approved dosing regimen in participants with relapsed or refractory multiple myeloma (RRMM) who have received at least 2 prior lines of therapy. The study will further characterize the risk of ocular toxicity and impact on efficacy measures and PK evaluations using alternative and approved dosing regimens.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Belantamab mafodotin
  • Bortezomib
  • Corneal events
  • Dexamethasone
  • DREAMM-16
  • Proteasome inhibitor
  • Immunomodulatory agent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the form (ICF).
  • Has or cytologically confirmed diagnosis of Multiple myeloma (MM), as defined by the IMWG.
  • Previously treated with at least 2 prior lines of MM therapy, including a proteasome inhibitor and an immunomodulatory agent.
  • Has at least 1 aspect of , as assessed by the central laboratory, defined as at least 1 of the following:

    • Urine M-protein excretion >=200 milligrams (mg)/24 hours (>=0.2 grams [g]/24 hours)
    • Serum M-protein concentration >=0.5 grams per deciliter (g/dL) (>=5.0 g/L)
    • Serum free light chain (FLC) assay: involved FLC level >=10 milligrams per deciliter (mg/dL) (>=100 mg/L) and an abnormal serum FLC ratio (less than [\<] 0.26 or greater than [>] 1.65).
  • Participants with a history of stem cell transplants are eligible for study participation provided the following eligibility criteria are met:

    • Transplant was > 100 days prior to study enrollment
    • No active infection(s)
    • Participant meets the remainder of the eligibility criteria
  • All prior treatment-related toxicities (defined by version [v] 6.0) must be Grade less than or equal to (\<=)1 at the time of treatment assignment, except for alopecia (any grade), neuropathy (Grade \<=2), or endocrinopathy managed with replacement therapy (any grade).
  • Is willing to use adequate male and female participants. Contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male participants are eligible to participate if they agree to the following during the Treatment Period and for at least 6 months after the last dose of belantamab mafodotin and 5 months after the last dose of bortezomib, whichever is longest, to allow for clearance of any altered sperm:

      • Refrain from donating fresh unwashed semen PLUS either
      • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), including any activity or passage of ejaculate to another person, and agree to remain abstinent. OR
      • Must agree to use contraception/barrier as detailed below:

      Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \<1 percent (%) per year when having sexual intercourse with a partner who can become pregnant and is not currently pregnant. Male participants should also use a condom when having sexual intercourse with pregnant females

    2. Female participants are eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:

      • Is a Person of non- (PONCBP) OR
      • Is a Person of childbearing potential (POCBP) and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, during the study intervention period and for at 4 months after the last dose of belantamab mafodotin or 8 months after the last dose of bortezomib, whichever is longest, and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.
      • A POCBP must have a negative highly sensitive serum pregnancy tests within 72 hours before the first dose of study intervention.
      • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a person with an early undetected pregnancy.
  • Is capable of giving signed informed consent.
  • Has an (ECOG) performance status 0-2.
  • Has adequate organ system functions as defined by the laboratory assessments.
  • Participants with a history of virus (HBV) and/or virus (HCV) and (HIV) exposure are eligible under specific conditions.

Exclusion criteria

Exclusion Criteria:

  • Intolerant to bortezomib
  • Diagnosis of systemic amyloid light chain amyloidosis, Waldenstrom's disease, polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes (POEMS) or Primary Plasma Cell Leukemia (defined as circulating plasma cells >5%)
  • Has previous or concurrent invasive other than Multiple myeloma (MM), except:

The disease must be considered medically stable for at least 2 years; or

  • The participant must not be receiving active therapy, other than hormonal therapy for this disease.

    • Known immediate or delayed reaction or idiosyncratic reaction to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
    • Evidence of active mucosal or internal bleeding.
    • Active infection requiring treatment
    • Any major surgery within 4 weeks prior to the first dose of study drug. Exception allowed for bone stabilizing surgery after consultation with Medical Monitor.
    • Active or history of venous and arterial thromboembolism within the past 3 months.
    • to or unwilling to undergo protocol-required anti-thrombotic prophylaxis.
    • Current corneal epithelial disease except for mild punctate keratopathy
    • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including laboratory abnormalities) that could interfere with participant's safety, obtaining or compliance to the study procedures.
    • Participants after prior stem cell transplant.
    • Has received prior belantamab mafodotin therapy.
    • Has received treatment with an agent within 14 days or 5 half-lives, whichever is shorter, preceding the first dose of study drug. This includes prior treatment with a monoclonal antibody and any other B-cell maturation antigen (BCMA) targeting-therapy. The only exception is emergency use of a short course of systemic (equivalent to, or less than: dexamethasone 40 mg/day for a maximum of 4 days) before treatment.
    • Systemic anti-myeloma therapy (including chemotherapy and systemic steroids); prior treatment with an anti-MM monoclonal antibody drug within 30 days of receiving the first dose of study intervention.
    • Plasmapheresis within 7 days prior to the first dose of study treatment. Screening laboratory values must be performed after last plasmapheresis
    • Has received any within 30 days of randomization/enrollment. Vaccination against Coronavirus Disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary.
    • Is currently enrolled or has participated in any other clinical study involving an investigational drug within 14 days or 5 half-lives (whichever is shorter) preceding the first dose of study intervention.
    • Known (HIV) infection, unless the participant can meet all of the following criteria:
  • Established anti-retroviral therapy for at least 4 weeks and HIV viral; load \<400 copies/milliliter (mL)
  • Cluster of differentiation 4 (CD4+) T-cell counts >=350 cells/microliter;
  • No history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months.

    • Is pregnant, plan to become pregnant, or breastfeeding.
    • Has an (ALT) value >2.5 times (ULN).
    • Has a total value >1.5 times ULN
    • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
    • Has a positive virus (HCV) antibody test result at screening or within 3 months prior to the first dose of study intervention unless HCV Ribonucleic acid (RNA) is negative, indicating past resolved HCV infection, including participants who have undergone curative treatment.
    • Has a positive HCV RNA test result at screening or within 3 months prior to the first dose of study intervention.
    • Has documented presence of surface antigen (HBsAg) and/or Hepatitis B virus antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention unless specific criteria are met.
    • Evidence of cardiovascular risk including any of the following:
  • Evidence of current untreated arrhythmias, including clinically significant (ECG) abnormalities including second degree (Mobitz Type II) or third degree atrioventricular block.
  • History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening
  • Class III or IV heart failure as defined by the (NYHA) functional classification system.
  • Uncontrolled hypertension • Has corrected (QTc) >450 milliseconds (msec) or QTc >480 msec for participants with bundle branch block.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Participants receiving Belantamab mafodotin dosing regimen 1 + Bortezomib + Dexamethasone

    Participants will receive dosing regimen 1 of Belantamab mafodotin in combination with Bortezomib and Dexamethasone

    Drug: Belantamab mafodotin · Drug: Dexamethasone · Drug: Bortezomib

  • Experimental
    Participants receiving Belantamab mafodotin dosing regimen 2 + Bortezomib + Dexamethasone

    Participants will receive dosing regimen 2 of Belantamab mafodotin in combination with Bortezomib and Dexamethasone.

    Drug: Belantamab mafodotin · Drug: Dexamethasone · Drug: Bortezomib

  • Experimental
    Participants receiving Belantamab mafodotin dosing regimen 3 + Bortezomib + Dexamethasone

    Participants will receive dosing regimen 3 of Belantamab mafodotin in combination with Bortezomib and Dexamethasone.

    Drug: Belantamab mafodotin · Drug: Dexamethasone · Drug: Bortezomib

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants with grade greater than or equal to (>=)3 corneal events assessed by keratopathy visual acuity (KVA) scale

    KVA scale ranges from 0 to 4 with higher score indicating greater severity of corneal events.

    Time frame: Up to approximately 4.5 years

  2. Percentage of participants with grade >=3 corneal events assessed by KVA scale up to Month 6

    KVA scale ranges from 0 to 4 with higher score indicating greater severity of corneal events.

    Time frame: Up to Month 6

  3. Percentage of Participants With Grade >=3 Corneal Events Assessed by KVA scale from 6 to 12 months

    KVA scale ranges from 0 to 4 with higher score indicating greater severity of corneal events. Data will be presented for the total number of participants with corneal events in each study group during 6 to 12 months.

    Time frame: From 6 to 12 months

Secondary outcomes

  1. Incidence of corneal events as assessed by KVA scale accounting for time on study treatment

    KVA scale ranges from 0 to 4 with higher scores indicating greater severity of corneal events.

    Time frame: Up to approximately 4.5 years

  2. Percentage of participants with corneal events as assessed by KVA scale

    KVA scale ranges from 0 to 4 with higher scores indicating greater severity of corneal events.

    Time frame: Up to approximately 4.5 years

  3. Number of recurrences of corneal events as assessed by KVA scale

    Number of recurrences of corneal events is defined as the total count of individual corneal event occurrences per participant over the study period. KVA scale ranges from 0 to 4 with higher scores indicating greater severity of corneal events.

    Time frame: Up to approximately 4.5 years

  4. Percentage of participants with post-baseline Best corrected visual acuity of 20/50, 20/100, 20/200

    Best corrected visual acuity test results are expressed as a fraction, such as 20/50. The top number is the testing distance of 20 feet, and the bottom number is the distance at which a person with average vision could read the same line. 20/50 indicates mild visual impairment, 20/100 indicates moderate visual impairment and 20/200 indicates severe visual impairment.

    Time frame: Up to approximately 4.5 years

  5. Number of participants with ocular adverse events and adverse events of special interest by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) Version 6.0

    Time frame: Up to approximately 4.5 years

  6. Number of participants with adverse events related dose modifications due to ocular toxicity by NCI-CTCAE Version 6.0

    Time frame: Up to approximately 4.5 years

  7. Number of participants with adverse events related dose modifications due to ocular toxicity by KVA scale

    KVA scale ranges from 0 to 4 with higher scores indicating greater severity of corneal events.

    Time frame: Up to approximately 4.5 years

  8. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed partial response (PR) or better as assessed by the investigator per International Myeloma Working Group (IMWG) criteria.

    Time frame: Up to approximately 4.5 years

  9. Percentage of participants with a confirmed Very good partial response (VGPR) or better

    Time frame: Up to approximately 4.5 years

  10. Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate, defined as the percentage of participants who are MRD-negative by next-generation sequencing (NGS) at 10\^-5 sensitivity threshold during the time of confirmed complete response (CR) or better response as assessed by the investigator per IMWG criteria.

    Time frame: Up to approximately 4.5 years

  11. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization until the earliest date of documented Progressive disease (PD) as assessed by the investigator per IMWG criteria or death due to any cause.

    Time frame: Up to approximately 4.5 years

  12. Number of participants with adverse events by NCI-CTCAE Version 6.0

    Time frame: Up to approximately 4.5 years

  13. Number of participants with clinically significant changes in hematology, chemistry, urinalysis parameters

    Time frame: Up to approximately 4.5 years

  14. Concentration at end of infusion (C-EOI) following administration of belantamab mafodotin

    Time frame: Up to approximately 4.5 years

  15. Area under the plasma concentration-time curve from time 0 to time t (AUC[0-t]) following administration of belantamab mafodotin

    Time frame: Up to approximately 4.5 years

  16. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of life questionnaire core 30 (EORTC QLQ-C30) score

    The EORTC QLQ-C30 score ranges from 0 to 100 with higher score indicates better functioning or a better overall state of health.

    Time frame: Baseline (Day 1) and up to approximately 4.5 years

  17. Maximum Post-baseline Patient-reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) Scores

    The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicities in participants in cancer clinical trials and is measured using a scale ranging from 0 to 100. Higher scores indicate poorer side effect experiences.

    Time frame: Up to approximately 4.5 years

  18. Mean change from Baseline in vision-related functioning as measured by ocular surface disease index (OSDI)

    The OSDI scores range from 0 to 100. Higher score indicates greater symptom severity.

    Time frame: Baseline (Day 1) and up to approximately 4.5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Feb 2029, 30 months later.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's planned 30 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 29, 2026
StartEst.
Aug 3, 2026
Primary completionEst.
Feb 28, 2029
CompletionEst.
Feb 11, 2031
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07614360
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Aug 3, 2026 (estimated)
Primary completion
Feb 28, 2029 (estimated)
Completion
Feb 11, 2031 (estimated)
Last update
Jun 24, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belantamab mafodotin · Dexamethasone · Bortezomib

Start the discussion